Trust Point’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.03M Buy
16,441
+2,529
+18% +$160K 0.08% 144
2026
Q2
$802K Buy
13,912
+4,748
+52% +$273K 0.07% 147
2026
Q1
$556K Buy
9,164
+1,158
+14% +$67.5K 0.05% 224
2025
Q4
$432K Buy
8,006
+461
+6% +$22.2K 0.03% 267
2025
Q3
$340K Sell
7,545
-386
-5% -$18K 0.03% 331
2025
Q2
$367K Buy
7,931
+514
+7% +$25.2K 0.03% 248
2025
Q1
$452K Sell
7,417
-2,006
-21% -$117K 0.04% 239
2024
Q4
$533K Buy
9,423
+172
+2% +$9.6K 0.04% 277
2024
Q3
$479K Buy
9,251
+906
+11% +$42.5K 0.04% 289
2024
Q2
$347K Sell
8,345
-2,418
-22% -$108K 0.03% 343
2024
Q1
$584K Sell
10,763
-6,846
-39% -$349K 0.05% 256
2023
Q4
$904K Buy
+17,609
New +$924K 0.07% 152

Other funds holding BMY

Trust Point's BMY Position: Q3 2026 in Review

Trust Point increased its Bristol-Myers Squibb (BMY) stake by 18% in Q3 2026, buying an estimated $160K and bringing the position to 16,441 shares worth $1.03M. The position accounts for 0.08% of the portfolio, ranked #144.

Trust Point first reported a position in BMY in Q4 2023 and has held it in 12 quarters since. 2,253 funds tracked by Wall St. Rank hold BMY as of Q3 2026.

  • Trust Point held 16,441 shares of Bristol-Myers Squibb worth $1.03M as of Q3 2026.
  • Trust Point bought 2,529 Bristol-Myers Squibb shares in Q3 2026, an estimated $160K.
  • Bristol-Myers Squibb made up 0.08% of Trust Point's portfolio in Q3 2026, its #144 holding.
  • Trust Point first reported a position in Bristol-Myers Squibb in Q4 2023 and has held it in 12 quarters since.
  • 2,253 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q3 2026.

Based on Trust Point's 13F filing for Q3 2026, filed 27 Oct 2026.